Auglavin PPH (400 mg + 57 mg)/5 ml Proszek do sporządzania zawiesiny doustnej Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

auglavin pph (400 mg + 57 mg)/5 ml proszek do sporządzania zawiesiny doustnej

zakłady farmaceutyczne polpharma s.a. - amoxicillinum + acidum clavulanicum - proszek do sporządzania zawiesiny doustnej - (400 mg + 57 mg)/5 ml

Auglavin PPH Extra (600 mg + 42,9 mg)/5 ml Proszek do sporządzania zawiesiny doustnej Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

auglavin pph extra (600 mg + 42,9 mg)/5 ml proszek do sporządzania zawiesiny doustnej

zakłady farmaceutyczne polpharma s.a. - amoxicillinum + acidum clavulanicum - proszek do sporządzania zawiesiny doustnej - (600 mg + 42,9 mg)/5 ml

Amylan 500 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

amylan 500 mg + 125 mg tabletki powlekane

viatris limited - amoxicillinum + acidum clavulanicum - tabletki powlekane - 500 mg + 125 mg

Amylan 875 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

amylan 875 mg + 125 mg tabletki powlekane

viatris limited - amoxicillinum + acidum clavulanicum - tabletki powlekane - 875 mg + 125 mg

Augmentin MFF (400 mg + 57 mg)/5 ml Proszek do sporządzania zawiesiny doustnej Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

augmentin mff (400 mg + 57 mg)/5 ml proszek do sporządzania zawiesiny doustnej

glaxosmithkline (ireland) limited - amoxicillinum + acidum clavulanicum - proszek do sporządzania zawiesiny doustnej - (400 mg + 57 mg)/5 ml

Hyrimoz União Europeia - polonês - EMA (European Medicines Agency)

hyrimoz

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - leki immunosupresyjne - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz może być podawany w monoterapii w przypadku nietolerancji metotreksatu lub przy stałym leczeniu z metotreksat niepraktyczne. adalimumab, jak wykazano, aby zmniejszyć szybkość progresji uszkodzenia stawów jak mierzy się promieniowanie x i ulepszać fizyczną funkcję, w momencie powołania, w połączeniu z metotreksatem. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz może być podawany w monoterapii w przypadku nietolerancji metotreksatu lub przy stałym leczeniu z metotreksat niepraktyczne. adalimumab nie została zbadana u pacjentów w wieku poniżej 2 lat. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab, jak wykazano, aby zmniejszyć prędkość postęp ośrodkowego uszkodzenia stawów, mierzonego za pomocą promieniowania rentgenowskiego u pacjentów z полиартикулярным rozwiązaniem symetryczny podtypów choroby i ulepszać fizyczną funkcję. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Polamoklav 875 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

polamoklav 875 mg + 125 mg tabletki powlekane

polfarmex s.a. - amoxicillinum + acidum clavulanicum - tabletki powlekane - 875 mg + 125 mg

Amoxicillin + Clavulanic Acid Aurovitas 875 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

amoxicillin + clavulanic acid aurovitas 875 mg + 125 mg tabletki powlekane

aurovitas pharma polska sp. z o.o. - amoxicillinum trihydricum + kalii clavulonas - tabletki powlekane - 875 mg + 125 mg

Auglavin PPH 500 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

auglavin pph 500 mg + 125 mg tabletki powlekane

zakłady farmaceutyczne polpharma s.a. - amoxicillinum + acidum clavulanicum - tabletki powlekane - 500 mg + 125 mg

Auglavin PPH 875 mg + 125 mg Tabletki powlekane Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

auglavin pph 875 mg + 125 mg tabletki powlekane

zakłady farmaceutyczne polpharma s.a. - amoxicillinum + acidum clavulanicum - tabletki powlekane - 875 mg + 125 mg